ArticlePloS one2015
Inverse agonistic action of 3-iodothyronamine at the human trace amine-associated receptor 5.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 82 citations in OpenAlex.
- A microbiome-derived olfactory signal regulates inter-male aggression and social dominance in mice.Current biology : CB · 2026Article
- TAAR5 Modulates Sensorimotor Recovery After Spinal Cord Injury.Biomedicines · 2026Article
- Localization, trafficking, and signaling of trace amine-associated receptor 2 in mouse neuroblastoma cells.Cellular signalling · 2026Article
- JP-14: A Trace Amine-Associated Receptor 1 Agonist with Anti-Metabolic Disorder Potential.International journal of molecular sciences · 2025Article
- Transcriptomic Analysis ofBrain sciences · 2025Article
- TAAR8 in the Brain: Implications for Dopaminergic Function, Neurogenesis, and Behavior.Biomedicines · 2025Article
- Targeting Odorant Receptors in Adipose Tissue with Food-Derived Odorants: A Novel Approach to Obesity Treatment.Foods (Basel, Switzerland) · 2024Review
- TAARs as Novel Therapeutic Targets for the Treatment of Depression: A Narrative Review of the Interconnection with Monoamines and Adult Neurogenesis.Biomedicines · 2024Review
- Trace Amine-Associated Receptors' Role in Immune System Functions.Biomedicines · 2024Review
- Trace amine-associated receptors (TAARs)2-9 knockout mice exhibit reduced wakefulness and disrupted REM sleep.Frontiers in psychiatry · 2024Article
- Nongenomic roles of thyroid hormones and their derivatives in adult brain: are these compounds putative neurotransmitters?Frontiers in endocrinology · 2023Review
- Improved cognitive performance in trace amine-associated receptor 5 (TAAR5) knock-out mice.Scientific reports · 2022Article
- Article
- Discovery of Novel Trace Amine-Associated Receptor 5 (TAAR5) Antagonists Using a Deep Convolutional Neural Network.International journal of molecular sciences · 2022Article
- Class A and C GPCR Dimers in Neurodegenerative Diseases.Current neuropharmacology · 2022Review
- Pattern of TAAR5 Expression in the Human Brain Based on Transcriptome Datasets Analysis.International journal of molecular sciences · 2021Article
- Article
- Activation of trace amine-associated receptor 1 selectively attenuates the reinforcing effects of morphine.British journal of pharmacology · 2021Article
- Commentary: Euthyroid Sick Syndrome in Patients With COVID-19.Frontiers in endocrinology · 2021Article
- 3-Iodothyronamine and Derivatives: New Allies Against Metabolic Syndrome?International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveApplication of 3-iodothyronamine (3-T1AM) results in decreased body temperature and body weight in rodents. The trace amine-associated receptor (TAAR) 1, a family A G protein-coupled receptor, is a target of 3-T1AM. However, 3-T1AM effects still persist in mTaar1 knockout mice, which suggest so far unknown further receptor targets that are of physiological relevance. TAAR5 is a highly conserved TAAR subtype among mammals and we here tested TAAR5 as a potential 3-T1AM target. First, we investigated mouse Taar5 (mTaar5) expression in several brain regions of the mouse in comparison to mTaar1. Secondly, to unravel the full spectrum of signaling capacities, we examined the distinct Gs-, Gi/o-, G12/13-, Gq/11- and MAP kinase-mediated signaling pathways of mouse and human TAAR5 under ligand-independent conditions and after application of 3-T1AM. We found overlapping localization of mTaar1 and mTaar5 in the amygdala and ventromedial hypothalamus of the mouse brain. Second, the murine and human TAAR5 (hTAAR5) display significant basal activity in the Gq/11 pathway but show differences in the basal activity in Gs and MAP kinase signaling. In contrast to mTaar5, 3-T1AM application at hTAAR5 resulted in significant reduction in basal IP3 formation and MAP kinase signaling. In conclusion, our data suggest that the human TAAR5 is a target for 3-T1AM, exhibiting inhibitory effects on IP3 formation and MAP kinase signaling pathways, but does not mediate Gs signaling effects as observed for TAAR1. This study also indicates differences between TAAR5 orthologs with respect to their signaling profile. In consequence, 3-T1AM-mediated effects may differ between rodents and humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.